MINNEAPOLIS, July 27 /PRNewswire/ -- Lutonix, Inc., a privately held medical device start-up, today announced that patient enrollment is underway for its three simultaneous first-in-human clinical trials. The three studies are designed to test whether the proprietary Lutonix Drug Coated Balloon (DCB) Catheter is safe and effective in the treatment of vascular narrowing.